Christine M. Fam
Bolder Biotechnology, Inc.(US)
Publications by Year
Research Areas
Effects of Radiation Exposure, PARP inhibition in cancer therapy, Hematopoietic Stem Cell Transplantation, Immune Response and Inflammation, interferon and immune responses
Most-Cited Works
- → Enhanced Circulating Half-Life and Antitumor Activity of a Site-Specific Pegylated Interferon-α Protein Therapeutic(2007)62 cited
- → PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), AND IL-11 (BBT-059) Analogs Enhance Survival and Hematopoietic Cell Recovery in a Mouse Model of the Hematopoietic Syndrome of the Acute Radiation Syndrome(2013)51 cited
- → PEGylated IL‐11 (BBT‐059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome(2018)33 cited
- → PEGylation Improves the Pharmacokinetic Properties and Ability of Interferon Gamma to Inhibit Growth of a Human Tumor Xenograft in Athymic Mice(2014)19 cited
- → Delayed effects of acute whole body lethal radiation exposure in mice pre-treated with BBT-059(2020)17 cited
- → Mitochondrial Degeneration and Autophagy Associated With Delayed Effects of Radiation in the Mouse Brain(2019)15 cited
- → Pharmacokinetic and Metabolomic Studies with a Promising Radiation Countermeasure, BBT-059 (PEGylated interleukin-11), in Rhesus Nonhuman Primates(2024)8 cited
- → Pharmacokinetic and Metabolomic Studies with BBT-059 in Nonhuman Primates Exposed to Total-Body Gamma Radiation(2024)2 cited